Conditions: Myocardial Infarction Reperfusion Injury
Keywords: Edaravone Randomized Control Trial ST-Elevation Myocardial Infarction Coronary Angioplasty
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 104
Healthy volunteers: no

Brief summary:
Early reperfusion therapy has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injuries. There is now increasing evidence that reactive oxygen species cause reperfusion injury. This study was designed to examine the effects of edaravone, a novel free radical scavenger, in patients with AMI.

Detailed description:
Initial AMI patients were randomly assigned to receive 30 mg of edaravone or a placebo intravenously just before reperfusion. We compared infarct size, using serial determination of serum biomarkers and Q wave formations, and the incidence of reperfusion arrhythmia between the groups. Cardiovascular event-free curves were estimated by Kaplan-Meier method. In addition, we determined serum thioredoxin levels, an oxidative stress marker, to assess the antioxidant effect of edaravone.

Arms:
arm 1: Edaravone Group arm 2: Placebo Group

Interventions: intervention 1: edaravone
Intervention descriptions: intervention 1: intravenous administration of 30mg Edaravone just before reperfusion therapy

Protocol document: